miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC)

被引:46
|
作者
Han, Yichao [1 ]
Li, Hecheng [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Thorac Surg, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China
关键词
Non-small cell lung cancer (NSCLC); microRNAs (miRNAs); early detection; biomarkers; MICRORNA SIGNATURES; NONINVASIVE BIOMARKERS; CIRCULATING MICRORNAS; TRAIL RESISTANCE; EGFR-TKIS; EXPRESSION; PLASMA; DIAGNOSIS; MIR-17-92; MIR-200C;
D O I
10.21037/jtd.2018.05.32
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Lung cancer is the most frequently diagnosed cancer and the most common cause of cancer death globally, of which 85% is non-small cell lung cancer (NSCLC). Early detection of NSCLC is essential to identify potential individuals for radical cure. Although low-dose computed tomography (LDCT) is recommended as standard screening with a mortality reduction of 20%, it displays a high false positive rate that poses an issue of overdiagnosis. MicroRNAs (miRNAs) are a group of small non-coding RNAs acting as important regulators in post-transcriptional gene expression and have been studied for their extensive role as novel biomarkers in NSCLC. Herein, we discuss the miRNA biology, its role in cancer, the potential of biomarkers both in cancer and NSCLC, and promising current publications of diagnostic biomarkers for early detection in NSCLC, especially studies in order to complement LDCT screening.
引用
收藏
页码:3119 / 3131
页数:13
相关论文
共 50 条
  • [21] Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer
    Klein, Mark
    Pragman, Alexa A.
    Wendt, Christine
    SEMINARS IN ONCOLOGY, 2022, 49 (3-4) : 285 - 297
  • [22] Serum microRNA Biomarkers for Detection of Non-Small Cell Lung Cancer
    Hennessey, Patrick T.
    Sanford, Tiffany
    Choudhary, Ashish
    Mydlarz, Wojciech W.
    Brown, David
    Adai, Alex Tamas
    Ochs, Michael F.
    Ahrendt, Steven A.
    Mambo, Elizabeth
    Califano, Joseph A.
    PLOS ONE, 2012, 7 (02):
  • [23] Detection and Identification of Potential Biomarkers of Non-small Cell Lung Cancer
    Yang, Yang
    Zhao, Song
    Fan, Yuxia
    Zhao, Feng
    Liu, Quan
    Hu, Wei
    Liu, Donglei
    Fan, Kai
    Wang, Jiaxiang
    Wang, Jianjun
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2009, 8 (06) : 455 - 465
  • [24] Analysis of non-small cell lung cancer (NSCLC) circulating biomarkers for monitoring early response to radiation therapy
    Purcell, Emma
    Niu, Zeqi
    Grzesik, Madeline
    Owen, Sarah
    Fairbairn, Heather
    Jolly, Shruti
    Nagrath, Sunitha
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 87 - 87
  • [25] LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER - BIOMARKERS IN UNRESECTABLE NSCLC
    Hopkins, B.
    Luca, K.
    Roper, J.
    Ridge, N.
    Sebastian, N.
    Kesarwala, A. H.
    Shelton, J.
    Stokes, W.
    Tian, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S567 - S567
  • [26] Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)
    Danzinger, Sabine
    Filipits, Martin
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 554 - 561
  • [27] Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
    Sutic, Maja
    Vukic, Ana
    Baranasic, Jurica
    Foersti, Asta
    Dzubur, Feda
    Samarzija, Miroslav
    Jakopovic, Marko
    Brcic, Luka
    Knezevic, Jelena
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (11):
  • [28] MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC)
    Liao, Jipei
    Shen, Jun
    Leng, Qixin
    Qin, Meng
    Zhan, Min
    Jiang, Feng
    THORACIC CANCER, 2020, 11 (03) : 762 - 768
  • [29] Actionable biomarkers in a non-small cell lung cancer (NSCLC) clinical pathway (CP).
    Ellis, Peter G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Actionable biomarkers in a non-small cell lung cancer (NSCLC) clinical pathway (CP).
    Ellis, Peter G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)